Memphasys Ltd (MEM) - Total Liabilities

Latest as of December 2025: AU$6.43 Million AUD ≈ $4.55 Million USD

Based on the latest financial reports, Memphasys Ltd (MEM) has total liabilities worth AU$6.43 Million AUD (≈ $4.55 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Memphasys Ltd - Total Liabilities Trend (2007–2025)

This chart illustrates how Memphasys Ltd's total liabilities have evolved over time, based on quarterly financial data. See Memphasys Ltd working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Memphasys Ltd Competitors by Total Liabilities

The table below lists competitors of Memphasys Ltd ranked by their total liabilities.

Company Country Total Liabilities
Avision Inc
TW:2380
Taiwan NT$1.93 Billion
Trinity Biotech plc
NASDAQ:TRIB
USA $158.43 Million
Walker River Resources Corp.
V:WRR
Canada CA$562.04K
Wise Group AB
ST:WISE
Sweden Skr132.58 Million
Clean & Science co. Ltd
KQ:045520
Korea ₩54.59 Billion
Close the Loop Ltd
AU:CLG
Australia AU$155.34 Million
Green Hydrogen Systems AS
CO:GREENH
Denmark Dkr1.54 Billion

Liability Composition Analysis (2007–2025)

This chart breaks down Memphasys Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Memphasys Ltd.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.14 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.60 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.62 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Memphasys Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Memphasys Ltd (2007–2025)

The table below shows the annual total liabilities of Memphasys Ltd from 2007 to 2025.

Year Total Liabilities Change
2025-06-30 AU$5.65 Million
≈ $4.00 Million
+1.10%
2024-06-30 AU$5.59 Million
≈ $3.96 Million
-23.21%
2023-06-30 AU$7.28 Million
≈ $5.15 Million
+12.49%
2022-06-30 AU$6.47 Million
≈ $4.58 Million
+8.38%
2021-06-30 AU$5.97 Million
≈ $4.23 Million
+287.19%
2020-06-30 AU$1.54 Million
≈ $1.09 Million
+101.68%
2019-06-30 AU$765.00K
≈ $541.28K
-11.62%
2018-06-30 AU$865.59K
≈ $612.46K
-88.76%
2017-06-30 AU$7.70 Million
≈ $5.45 Million
+34.76%
2016-06-30 AU$5.72 Million
≈ $4.05 Million
-6.25%
2015-06-30 AU$6.10 Million
≈ $4.31 Million
-24.67%
2014-06-30 AU$8.10 Million
≈ $5.73 Million
+21.88%
2013-06-30 AU$6.64 Million
≈ $4.70 Million
+51.31%
2012-06-30 AU$4.39 Million
≈ $3.11 Million
+22.74%
2011-06-30 AU$3.58 Million
≈ $2.53 Million
-26.63%
2010-06-30 AU$4.87 Million
≈ $3.45 Million
-20.81%
2009-06-30 AU$6.16 Million
≈ $4.36 Million
+55.65%
2008-06-30 AU$3.95 Million
≈ $2.80 Million
+48.50%
2007-06-30 AU$2.66 Million
≈ $1.88 Million
--

About Memphasys Ltd

AU:MEM Australia Medical Devices
Market Cap
$12.09 Million
AU$17.08 Million AUD
Market Cap Rank
#26456 Global
#1247 in Australia
Share Price
AU$0.01
Change (1 day)
+0.00%
52-Week Range
AU$0.00 - AU$0.01
All Time High
AU$0.37
About

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port… Read more